Kalray Unveils Its K200-LP Latest Acceleration Card for Data Centers
16.6.2021 08:30:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider in the new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, today unveils its new K200-LP™ acceleration card. K200-LP™ is a new member of Kalray’s fully programmable multi-purpose acceleration card family, based on its unique MPPA® processor, and offering an unprecedented level of performance and targeting the booming NVMe based storage market as its first implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615006166/en/
Kalray's K200-LP Acceleration Card (Photo: Kalray)
The explosion of data, driven by demanding services and applications using AI and data analytics, is putting a lot of pressure on Cloud and Edge Data Center’s networking and storage to feed the demanding compute intensive resources. The primary needs are to reduce latency, enhance bandwidth and IOPs1 performance as well as offloading host CPUs, at best cost.
Data centers are looking for solutions that enable high performance, low power, cost effectiveness and openness to scale and match demand on data availability. The K200-LP™ acceleration card is Kalray’s solution to address these exacting demands for their data center customers.
Eric Baissus, President and CEO of Kalray, said: “We are proud to unveil our new K200-LP™ acceleration card, based on our MPPA® processor. This family of Ethernet/PCIe acceleration cards are natively capable of managing multiple workloads with no bottleneck to enable smarter, more efficient, and energy-wise applications on Cloud and Edge data centers. To address the new generation of storage array solutions for Cloud and Edge, K200-LP™ is a game changer solution in terms of performance per Watt and per dollar.”
To improve and optimize overall IT infrastructures, the industry has moved increasingly towards disaggregated storage. Put simply, separating compute resources and storage resources.
1 IOPS is the numbers of Input/Output operations per second and is a performance measurement used to characterize computer storage devices.
Most advanced All-Flash-Array solutions today use multiple adapter cards around a x86 that runs storage services. Kalray manages to run all the critical functions of a disaggregated storage appliance on one single chip: the Kalray MPPA® processor. Advanced Data Processing Units (DPU) like MPPA® and associated acceleration cards can run, efficiently and on a cost-optimized manner versus traditional x86, new protocols such as NVMe and NVMe-over-Fabric to access and unleash the full capability of SSDs wherever they are located in the Data Center as if there were locally attached.
Whereas the industry has defined a new NVMe protocol to support the latest generation of ultra-fast storage devices, existing traditional technologies are not capable of exposing the full capability of NVMe-based SSDs. Kalray’s K200-LP™ smart storage card has been built from the ground-up to support those breaking through data protocols. Based on Kalray MPPA’s processor, K200-LP™ is also the perfect solution for storage array appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per $.
Kalray’s K200-LP™ acceleration card is a low-profile, 2x 100GB ethernet, PCIe Gen4 card that can deliver more than 2 MIOPS and 12 GB/s per card (both RoCE and TCP) with a latency as low as 30 microseconds. K200-LP™ has been developed by Kalray and is manufactured by Taiwanese Wistron, one of the largest manufacturers of electronic cards and data center servers in the world.
Kalray’s K200-LP™ smart storage card and associated tools are available now.
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, leading provider in a new generation of processors specialized in Intelligent Data Processing from Cloud to Edge. Kalray MPPA® Intelligent Processors are able to capture and analyze on the fly massive data flows, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as intensive mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors from Cloud to Edge: modern data centers, 5G telecom networks, autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, acceleration cards and a software suite, for a broad spectrum of customers such as next generation data center equipment manufacturers and service providers, system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615006166/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
+33 (0)4 76 18 90 71
ACTUS finance & communication
Jérôme FABREGUETTES-LEIB
kalray@actus.fr
+33 1 53 67 36 78
MEDIA
Loic HAMON
communication@kalrayinc.com
+33 (0)4 76 18 90 71
ACTUS finance & communication
Serena BONI
sboni@actus.fr
+33 (0)4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom